Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.64 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.64 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | ACVR1B | P36896 | 9/20 | 0.44 |
| ▸ | ACVRL1 | P37023 | 8/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.44 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | BUB1 | O43683 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14516423 | 0.87 | TGFBR1 (0.51) | TGFBR1PRKD3PRKD1PRKD2FLT1 | |
| SCHEMBL2491506 | 0.87 | TGFBR1 (0.54) | TGFBR1PRKD3PRKD1PRKD2MAPK9 | |
| SCHEMBL5551403 | 0.86 | TGFBR1 (0.74) | TGFBR1PRKD3PRKD1PRKD2FLT1 | |
| SCHEMBL5954510 | 0.84 | TGFBR1 (0.59) | TGFBR1MAPK9MAPK10ACVR1BACVRL1 | |
| SCHEMBL2125433 | 0.83 | TGFBR1 (0.70) | TGFBR1PRKD3PRKD1PRKD2FLT1 | |
| SCHEMBL2128393 | 0.83 | TGFBR1 (0.66) | TGFBR1PRKD3PRKD1PRKD2FLT1 | |
| SCHEMBL5954799 | 0.83 | TGFBR1 (0.57) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL2127316 | 0.81 | TGFBR1 (0.63) | TGFBR1PRKD3PRKD1PRKD2FLT1 | |
| SCHEMBL17816391 | 0.81 | TGFBR1 (0.51) | TGFBR1PRKD3PRKD1PRKD2FLT1 | |
| SCHEMBL8347154 | 0.81 | TGFBR1 (0.70) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869037-B1 | HETEROBICYLIC INHIBITORS OF HVC | TIBOTEC PHARM LTD (IE) | 2011-07-27 | — | — | EP | claimed |
| US-20080182863-A1 | Fused Bicyclic Inhibitors of Hcv | TIBOTEC BVBA (BE) | 2008-07-31 | — | — | US | claimed |
| EP-1869037-A1 | HETEROBICYLIC INHIBITORS OF HVC | Tibotec Pharmaceuticals Ltd. (IE) | 2007-12-26 | — | — | EP | claimed |
| WO-2006100310-A1 | HETEROBICYLIC INHIBITORS OF HCV | TIBOTEC PHARMACEUTICALS LTD (IE) | 2006-09-28 | — | — | WO | claimed |
| US-8030318-B2 | e.g. 4-[2-(5-Chloro-2-fluoro-phenyl)-7-(2-dimethylamino-ethylamino)-pyrido-[2,3-d]pyrimidin-4-ylamino]-nicotinic acid; viricide; transforming growth factor-beta inhibitor; hepatitis C infection; fibroproliferative conditions: fibrosis, glomerulonephritis, diabetic nephropathy, and certain cancers | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-10-04 | — | — | US | disclosed |
| US-8030318-B2 | e.g. 4-[2-(5-Chloro-2-fluoro-phenyl)-7-(2-dimethylamino-ethylamino)-pyrido-[2,3-d]pyrimidin-4-ylamino]-nicotinic acid; viricide; transforming growth factor-beta inhibitor; hepatitis C infection; fibroproliferative conditions: fibrosis, glomerulonephritis, diabetic nephropathy, and certain cancers | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-10-04 | — | — | US | disclosed |
| US-8030318-B2 | e.g. 4-[2-(5-Chloro-2-fluoro-phenyl)-7-(2-dimethylamino-ethylamino)-pyrido-[2,3-d]pyrimidin-4-ylamino]-nicotinic acid; viricide; transforming growth factor-beta inhibitor; hepatitis C infection; fibroproliferative conditions: fibrosis, glomerulonephritis, diabetic nephropathy, and certain cancers | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-10-04 | — | — | US | disclosed |
| EP-1869037-B1 | HETEROBICYLIC INHIBITORS OF HVC | TIBOTEC PHARM LTD (IE) | 2011-07-27 | — | — | EP | disclosed |
| US-20080182863-A1 | Fused Bicyclic Inhibitors of Hcv | TIBOTEC BVBA (BE) | 2008-07-31 | — | — | US | disclosed |
| US-20080182863-A1 | Fused Bicyclic Inhibitors of Hcv | TIBOTEC BVBA (BE) | 2008-07-31 | — | — | US | disclosed |
| US-20080182863-A1 | Fused Bicyclic Inhibitors of Hcv | TIBOTEC BVBA (BE) | 2008-07-31 | — | — | US | disclosed |
| EP-1869037-A1 | HETEROBICYLIC INHIBITORS OF HVC | Tibotec Pharmaceuticals Ltd. (IE) | 2007-12-26 | — | — | EP | disclosed |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7232824-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232824-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232824-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20070066632-A1 | Fused bicyclic inhibitors of TGFbeta | SCIOS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2006100310-A1 | HETEROBICYLIC INHIBITORS OF HCV | TIBOTEC PHARMACEUTICALS LTD (IE) | 2006-09-28 | — | — | WO | disclosed |
| US-20050096333-A1 | Quinazoline derivatives as medicaments | SCIOS, INC. | 2005-05-05 | — | — | US | disclosed |
| WO-2005032481-A2 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182863-A1 | Fused Bicyclic Inhibitors of Hcv | HAVCR2, GTF3C4, CUL4A | TGFBR1 3950/4885PRKD3 4022/4885PRKD1 4348/4885 |
| US-20050096333-A1 | Quinazoline derivatives as medicaments | HRH4, HRH2, HRH3 | TGFBR1 70/4885PRKD3 3011/4885PRKD1 3332/4885 |
| US-20070066632-A1 | Fused bicyclic inhibitors of TGFbeta | TGFBR1, TGFB1, SMAD2 | TGFBR1 1/4885PRKD3 3166/4885PRKD1 3999/4885 |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SMAD3, SMAD2, TGFB2 | TGFBR1 8/4885PRKD3 1661/4885PRKD1 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.